What is Mounjaro? Understanding the Latest in Diabetes Management

Last reviewed: July 13, 2026

Last updated: July 13, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Tirzepatide represents a significant advancement in metabolic therapy by simultaneously targeting GLP-1 and GIP receptors—two distinct hormone signaling pathways that control appetite, blood sugar, and weight regulation. Clinical trials have demonstrated that tirzepatide produces greater A1C reductions and weight loss compared to single-action GLP-1 medications. PlexusDx delivers compounded tirzepatide injections through licensed 503A pharmacies, making this dual-receptor therapy accessible without insurance across all 50 states.

How Tirzepatide Works: Dual-Receptor Mechanism

Tirzepatide functions as a GLP-1 and GIP receptor agonist, meaning it activates two distinct signaling pathways in your body simultaneously. The GLP-1 pathway slows stomach emptying, increases feelings of fullness, and triggers insulin release when blood sugar rises. The GIP pathway enhances insulin secretion and may directly improve how your body handles glucose metabolism. Together, these two mechanisms create a more comprehensive effect on appetite suppression and metabolic regulation than medications targeting only one pathway.

This dual-action design explains why tirzepatide users often experience both improved blood sugar control and significant weight reduction in clinical studies. The medication works at the cellular level to enhance your body's natural ability to manage energy intake and glucose homeostasis. Unlike older diabetes drugs that work through a single mechanism, tirzepatide's broader approach addresses multiple points of dysregulation simultaneously. This makes it particularly effective for individuals with type 2 diabetes who also carry excess body weight.

Tirzepatide vs. Semaglutide: Key Clinical Differences

Semaglutide activates only the GLP-1 receptor, whereas tirzepatide activates both GLP-1 and GIP receptors. In the SURPASS clinical trial program, tirzepatide produced greater reductions in A1C levels and body weight than semaglutide at comparable timepoints. Patients using tirzepatide achieved average weight loss ranging from 15% to 22% of their starting body weight, depending on the dose and study duration. The additional GIP receptor activation appears to contribute to superior metabolic improvements in a subset of patients.

The PlexusDx Precision Peptide Genetic Test analyzes GLP1R, and GIPR — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Clinical Evidence: Tirzepatide Efficacy and Safety

The SURPASS trial series enrolled over 13,000 participants across multiple studies examining tirzepatide's effects on type 2 diabetes management and weight loss. Participants receiving tirzepatide 15 mg weekly experienced average A1C reductions of 2.2 percentage points over 40 weeks, compared to 0.9 percentage points for semaglutide 1.0 mg. Weight loss with tirzepatide ranged from 8 kg in early trials to 22 kg in longer-term studies, with improvements in cardiovascular risk markers including blood pressure and lipid profiles. These results have made tirzepatide one of the most extensively studied GLP-1 receptor agonist compounds in medical literature.

Common side effects observed in trials included nausea, vomiting, and diarrhea, particularly during dose escalation periods. Most gastrointestinal side effects were mild to moderate and decreased over time as patients' bodies adapted to the medication. Serious adverse events were rare and not significantly different between tirzepatide and comparator groups. Long-term safety data supports tirzepatide as a well-tolerated option for individuals seeking durable weight loss and blood sugar control without major safety concerns.

Personalized Dosing and PlexusDx Precision Peptide Testing

The PlexusDx Precision Peptide Genetic Test analyzes GLP1R (rs6923761), and GIPR (rs1800437) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

PlexusDx delivers compounded tirzepatide injections at $289/mo (or $249/mo on the 6-month plan) flat—your dose may need to go up as your body adapts, but your monthly price remains the same. This pricing model eliminates surprise cost increases as clinicians optimize your therapy. PlexusDx also offers GLP-Squared Injection, a dual compound combining semaglutide and tirzepatide for patients who benefit from both medications simultaneously, at $289/mo month-to-month, or from $249/mo on the 6-month plan. All medications are prepared by licensed 503A compounding pharmacies and available across all 50 states without insurance or membership requirements.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is tirzepatide the same as Mounjaro?

Tirzepatide is the active pharmaceutical ingredient in Mounjaro, Eli Lilly's branded injectable medication. PlexusDx provides compounded tirzepatide prepared by licensed 503A pharmacies, offering the same active ingredient at lower cost at $289/mo month-to-month, or from $249/mo on the 6-month plan. Compounded tirzepatide is not FDA-branded but contains identical pharmaceutical-grade tirzepatide manufactured to strict quality standards.

How much weight can I expect to lose with tirzepatide?

No — the Precision Peptide Genetic Test does not predict your response to Mounjaro or any specific medication. It analyzes pathway-level variants (GLP1R, and GIPR) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

How much does PlexusDx compounded tirzepatide cost?

PlexusDx compounded tirzepatide injections are $289/mo month-to-month, or from $249/mo on the 6-month plan flat across all commitment tiers. Your dose may increase as treatment progresses, but your monthly price stays the same—no hidden costs as clinicians optimize your therapy. The medication is HSA/FSA eligible and available in all 50 states without insurance or membership fees.

What are the most common side effects of tirzepatide?

Nausea, vomiting, constipation, and diarrhea occur most frequently, especially during dose escalation, but typically decrease within 2 to 4 weeks as your body adapts. Serious side effects are rare. PlexusDx clinicians monitor your tolerance and adjust dosing schedules to minimize discomfort while maintaining therapeutic benefit.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GLP1R (rs6923761), and GIPR (rs1800437)) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Mounjaro For Type 2 Diabetes
• What Are The Genetic Factors In Diabetic Neuropathy And Their Management Impact In Diabetes
• Hers Mounjaro
• Hims Mounjaro

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.